OrthoGel, a medical device company, is evaluating a partnership with SpongeBob, a sponge manufacturer, to create a combined hydrogel-sponge product for surgical recovery. The key analysis involves determining whether the deal creates value, what price OrthoGel should charge SpongeBob, and whether OrthoGel is capturing an appropriate share of the combined product’s value proposition.
Key Insights:
- Value creation is driven primarily by OrthoGel’s proprietary hydrogel, not the commodity sponge component
- The combined product has 15% higher WTP ($69-$92 vs $60-$80), but pricing must account for SpongeBob’s cost structure ($2/sponge) and margin expectations
- Critical assumption testing: the case specifies 3 sponges per vial, which materially changes value distribution and pricing (1 sponge scenario yields different economics than 3-sponge scenario)
- Strong candidates calculate OrthoGel’s current margin ($45/unit) and ensure the deal price ($48.50+) maintains or improves this while recognizing SpongeBob’s margin compression from 80% to 36-47%
- Non-financial considerations include manufacturing feasibility, regulatory implications, and whether alternative sponge manufacturers offer better terms